LGR5 and colorectal cancer: According to a 2022 report by McPeake and colleagues, LGR5-redirected CAR-Ts might be promising therapeutics for the treatment of colorectal cancer as administration of CNA3103 into preclinical mouse models mediated complete remission in all of the subjects (100%) (63).